P-093: Exclusive enteral nutrition and infliximab for treatment of ulcerative colitis with extraintestinal manifestation
نویسندگان
چکیده
منابع مشابه
Economic Evaluation of Infliximab for Treatment of Refractory Ulcerative Colitis in Iran: Cost-Effectiveness Analysis
The aim of this study is to assess cost-effectiveness of infliximab, compared with conventional treatments in patients with moderate to severe Ulcerative Colitis (UC) in Iran. We developed an analytical decision model with a 5-year-time horizon to follow up 1000 hypothetical patients, in order to estimate treatment costs and outcomes. Hypothetical patients, were individuals with moderate to sev...
متن کاملInfliximab for treatment of pyoderma gangrenosum with ulcerative colitis.
The recent case report published in the JCC on using combined infliximab and surgery in treatment of pyoderma gangrenosum with ulcerative colitis is interesting.1Andrisani et al. proposed for the effectiveness of this regimen.1The possibility of adverse events on the other side on using infliximab should also be mentioned. The practitioner has to weigh between the usefulness and possible advers...
متن کاملExtraintestinal Manifestations of Ulcerative Colitis
Inflammatory bowel disease (IBD) consists predominantly of ulcerative colitis (UC) and Crohn’s disease (CD), which are clinically distinguished by intestinal localization, local features of inflammation, a profile of complications, and familial aggregation. UC is characterized by recurring episodes of continuous inflammation limited to the mucosal layer of the colon and rectum, and approximatel...
متن کاملInfliximab in ulcerative colitis
Infliximab, a monoclonal anti-TNF-alpha antibody, is commonly used for treatment of moderate to severe Crohn's disease (CD). Its role in the treatment for ulcerative colitis (UC) remains controversial. We review the role of TNF-alpha in the pathogenesis of UC and describe the randomized, double-blind, placebo-controlled trials and systematic reviews that assess the efficacy of infliximab in the...
متن کاملInfliximab in ulcerative colitis
This paper critically reviews the evidence for established (5-aminosalicylic acid [5-ASA] compounds, corticosteroids, immunomodulators, calcineurin inhibitors) and emerging novel therapies-including biological therapies-directed at cytokines (eg, infliximab, adalimumab, certolizumab pegol) and receptors (eg, visilizumab, abatacept) involved in T-cell activation, selective adhesion molecule bloc...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Crohn's and Colitis
سال: 2014
ISSN: 1873-9946
DOI: 10.1016/s1873-9946(14)50121-3